Drugs /

autologous m-cenk

Back to Drugs List

Overview

NCI Definition [1]:
A population of cryopreserved, autologous CD56-positive memory cytokine-enriched natural killer (NK) cells (m-ceNKs), armed with NK cell-activating surface receptors, with potential immunomodulating and antitumor activities. Autologous NK cells are pre-activated ex vivo with a cytokine cocktail, which induces the differentiation of the NK cells into immune-memory m-ceNKs, which possess a unique phenotype. The pretreated NKs exhibit enhanced cytotoxicity and increased interferon-gamma (IFN-g) production. Upon administration, the autologous m-ceNKs may recognize and kill tumor cells.

Clinical Trials

View Clinical Trials for autologous m-cenk

Autologous m-cenk has been investigated in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial investigating autologous m-cenk, 1 is phase 1 (1 open).

Malignant solid tumor is the most common disease being investigated in autologous m-cenk clinical trials [2].

Drug Details

Synonyms [2]:
autologous memory cytokine enriched natural killer cells, autologous cytokine-induced memory-like nks, autologous cytokine-induced memory-like nks, m-cenk (tm), autologous memory cytokine-enriched nk cells, m-cenk cells

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/. [2018-07-30] [2018-08-02].

2. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.